After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Antibody-drug conjugates hitting this target abound.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
